About the Disease
Atypical Hemolytic-uremic Syndrome (aHUS) is a disease characterized by low red blood cell count, low platelet count and inability to process and excrete waste products from the blood. Symptoms result from tiny blood clots that form in small blood vessels in the body which impede proper blood flow to various organs of the body, especially the kidneys. As a result, people with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease in about half of all cases.
About our Patient Care
Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide
counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.
In-Home Patient- and Family-Centric Care
We administer a nationwide nursing network, allowing patients to pursue in-home treatment or receive training on self-administrated drugs. Our nurses are ideally positioned to establish a partnership with patients and their families in order to provide clinical education and coaching that strengthen the patient's capacity to achieve therapy goals.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.
We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Brand Name | Soliris
Manufacturer | Alexion
Route of Administration | Intravenous (IV) infusion
Approved Indication | Treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy.
Self-Administration | No
Product Website | info.soliris.net/home/